The diseases which EVI is targeting are some of the most widespread and entrenched of the developing world. All disproportionately affect the marginalised and vulnerable. They are both cause and consequence of poverty.
The past decade has seen unprecedented global investment in control of these diseases, both in roll-out of proven technologies and in research into new interventions. There have been some successes, but perennial issues such as drug and insecticide resistance remain. Achieving significant, sustained reductions in disease burden and transmission, let alone elimination, will in most cases require an effective and affordable vaccine.
The challenges for development of vaccines for diseases of poverty are significant for researchers, donors and industry. EVI is finding solutions with all these stakeholders.